ProBioGen and Evotec Technologies Successful Completion of Joint Development Collaboration
Berlin and Hamburg, Germany, 29 August 2006
ProBioGen AG and Evotec Technologies GmbH have announced the successful completion of their collaboration – the joint evaluation of methods and instrumentation for the selection of high producer cells. ProBioGen could show based on it’s cell-based assay technology, know how and expertise in cGMP cell culture that Evotec's Cytocon™ device can be employed for the selection of high producer cell lines used in pharmaceutical development and manufacturing applications.
Both companies emphasize their great satisfaction with the mutually inspiring and successful cooperation, and scientists from both companies professed their interest in future common projects.
About ProBioGen AG
ProBioGen is a specialist for cell line design, viral vectors, and the manufacture of glycoproteins for the biopharmaceutical industry. The German biotechnology company is headquartered in Berlin. Its range of products and services include the development of highly productive cell lines, the design of novel cell lines from primary tissue, the manufacture of glycoproteins for clinical studies and R&D, as well as the production of viral vectors and antibodies for in vitro diagnostics. ProBioGen possesses the manufacturing authorization for pharmaceutically usable active substances for testing in clinical studies and meets the quality standards recommended by the EU (EMEA) and the FDA. A certified cGMP multipurpose facility is available for contract production of biopharmaceutical active substances. The Company is specialized in mammalian cells and combines the know-how of molecular biology scientists with the experience of experts in cell culture technology and process engineering. ProBioGen thus accompanies its clients from the early development of product candidates up to late clinical testing phase.
About Evotec Technologies
Evotec Technologies GmbH , subsidiary of Evotec AG, is the world’s leading provider of confocal detection devices (Opera™, Clarina™, Insight™ Cell), cell handling devices (CytoClone™, Cytocon™) and ultra-High-Throughput Screening (uHTS) systems (EVOscreen®, plate::explorer™). The Company’s product portfolio is focused on high-end technologies for automated cell biology. Its outstanding expertise in detection coupled with sophisticated automation skills, integrating hardware, software and bioware modules, makes the Company a clear leader for automated cell analysis. Evotec Technologies employs 80 people, primarily at its main site in Hamburg, Germany. www.evotec-technologies.com
Forward-looking statements
This press release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives, and similar intentions and beliefs and other statements regarding the Companies’ expectations, goals, beliefs, intentions and the like, which involve inherent risks, uncertainties and assumptions regarding the Companies’ operations and conditions in the markets they serve. The Companies’ do not undertake any obligation to update these forward-looking statements.
Contact
ProBioGen AG
Michael Schlenk
ProBioGen AG
Goethestraße 54
13068 Berlin
Germany
Tel. +49 (30) 924006-16
Fax +49 (30) 924006-19
e-mail michael.schlenk@probiogen.de
www.probiogen.de
Evotec Technologies GmbH
Dr. Günther Bauer
Evotec Technologies GmbH
Schnackenburgallee 114
22525 Hamburg
Germany
Tel. +49 (0) 40 560 81 – 321
Fax +49 (0) 40 560 81-333
e-mail guenter.bauer@evotec-technologies.com
www.evotec-technologies.com